What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.

Purpose The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial. The individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments. Methods All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixed- and random-effects frequentist network meta-analysis models were applied. Results The three treatments with the highest probability of benefit on overall survival (OS) were CRT-AC, followed by CRT and IC-CRT, with respective hazard ratios (HRs [95% CIs]) compared with RT alone of 0.65 (0.56 to 0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS, progression-free survival (PFS), locoregional control, and distant control (DC) were, respectively, 0.85 (0.68 to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and the best for DC. CRT never ranked first. HRs of CRT compared with IC-CRT for OS, PFS, locoregional control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55 (0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity. Conclusion The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points. The addition of IC to CRT achieved the highest effect on DC.

[1]  Emily Newman,et al.  PROSPERO International prospective register of systematic reviews , 2017 .

[2]  Johannes B Reitsma,et al.  GetReal in network meta‐analysis: a review of the methodology , 2016, Research synthesis methods.

[3]  J. Pignon,et al.  Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis", published in Eur J Cancer 51 (2015), 1570-1579. , 2016, European journal of cancer.

[4]  X. Bian,et al.  The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials , 2016, OncoTargets and therapy.

[5]  Patrick Royston,et al.  Meta‐analysis of time‐to‐event outcomes from randomized trials using restricted mean survival time: application to individual participant data , 2015, Statistics in medicine.

[6]  Gerta Rücker,et al.  Ranking treatments in frequentist network meta-analysis works without resampling methods , 2015, BMC Medical Research Methodology.

[7]  Ying Sun,et al.  Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials , 2015, Journal of Cancer.

[8]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[9]  Jun Ma,et al.  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. , 2015, The Lancet. Oncology.

[10]  K. Soo,et al.  Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[11]  Jun Ma,et al.  OC-003: What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis , 2015 .

[12]  Kelvin K. W. Chan,et al.  Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. , 2015, European journal of cancer.

[13]  Y Sun,et al.  A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Joseph Beyene,et al.  Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study , 2014, Clinical epidemiology.

[15]  H. Sze,et al.  Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  H. Ying,et al.  A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. , 2014, Oral oncology.

[17]  U. Dirnagl,et al.  Biomedical research: increasing value, reducing waste , 2014, The Lancet.

[18]  Panagiota Spyridonos,et al.  Graphical Tools for Network Meta-Analysis in STATA , 2013, PloS one.

[19]  W. Liang,et al.  Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Ying Sun,et al.  Progress report of a randomized trial comparing long‐term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China , 2013, Cancer.

[21]  Gerta Rücker,et al.  Network meta‐analysis, electrical networks and graph theory , 2012, Research synthesis methods.

[22]  R. Sun,et al.  A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. , 2012, Oral oncology.

[23]  V. Grégoire,et al.  Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.

[24]  Ying Sun,et al.  Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[25]  T. Ciuleanu,et al.  Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  V. Grégoire,et al.  Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R. Sun,et al.  Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. , 2011, Journal of the National Cancer Institute.

[28]  J. Pignon,et al.  Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. , 2011, Journal of clinical epidemiology.

[29]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[30]  B. O'Sullivan,et al.  A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  B. O'Sullivan,et al.  Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. , 2010, Journal of the National Cancer Institute.

[32]  A. King,et al.  Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Georgia Salanti,et al.  Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. , 2008, Journal of the National Cancer Institute.

[34]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[36]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[37]  J. Sham,et al.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[39]  S. Fukuda,et al.  A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma , 2002, Cancer.

[40]  Yue-Cune Chang,et al.  A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. , 2002, International journal of radiation oncology, biology, physics.

[41]  S. Thongprasert,et al.  Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Associati , 1998 .

[42]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Vumca I Trial.  Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. , 1996, International journal of radiation oncology, biology, physics.

[44]  S. Leung,et al.  A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. , 1995, International journal of radiation oncology, biology, physics.

[45]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[46]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[47]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.